SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
M Lipsitch, F Krammer, G Regev-Yochay… - Nature Reviews …, 2022 - nature.com
Breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) in fully vaccinated individuals are receiving intense scrutiny because of their importance …
2) in fully vaccinated individuals are receiving intense scrutiny because of their importance …
Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines
R Fraser, A Orta-Resendiz, A Mazein… - Trends in molecular …, 2023 - cell.com
SARS-CoV-2 vaccination significantly reduces morbidity and mortality, but has less impact
on viral transmission rates, thus aiding viral evolution, and the longevity of vaccine-induced …
on viral transmission rates, thus aiding viral evolution, and the longevity of vaccine-induced …
Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19
MJ Levin, A Ustianowski, S De Wit… - … England Journal of …, 2022 - Mass Medical Soc
Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …
[HTML][HTML] Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
Background Many countries are experiencing a resurgence of COVID-19, driven
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
[HTML][HTML] Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million …
U Agrawal, S Bedston, C McCowan, J Oke, L Patterson… - The Lancet, 2022 - thelancet.com
Background Current UK vaccination policy is to offer future COVID-19 booster doses to
individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups …
individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups …
SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients
DF Ruether, GM Schaub, PM Duengelhoef… - Clinical …, 2022 - Elsevier
Background & Aims Detailed information on the immune response after second vaccination
of cirrhotic patients and liver transplant (LT) recipients against severe acute respiratory …
of cirrhotic patients and liver transplant (LT) recipients against severe acute respiratory …
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab …
S Lin, NA Kennedy, A Saifuddin, DM Sandoval… - Nature …, 2022 - nature.com
Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection
and impair protective immunity following pneumococcal and influenza vaccination. Here we …
and impair protective immunity following pneumococcal and influenza vaccination. Here we …
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in …
Background In this study we aimed to monitor the risk of breakthrough SARS-CoV-2
infection in patients with MS (pwMS) under different DMTs and to identify correlates of …
infection in patients with MS (pwMS) under different DMTs and to identify correlates of …
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a …
Background COVID-19 vaccines have robust immunogenicity in the general population.
However, data for individuals with immune-mediated inflammatory diseases who are taking …
However, data for individuals with immune-mediated inflammatory diseases who are taking …
[HTML][HTML] Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases
RM Dayam, JC Law, RL Goetgebuer, GYC Chao… - JCI insight, 2022 - ncbi.nlm.nih.gov
BACKGROUND Limited information is available on the impact of immunosuppressants on
COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMID) …
COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMID) …